Cidara Therapeutics, Inc. (CDTX): Price and Financial Metrics


Cidara Therapeutics, Inc. (CDTX): $0.45

-0.01 (-2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CDTX POWR Grades


  • CDTX scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.21% of US stocks.
  • The strongest trend for CDTX is in Quality, which has been heading down over the past 160 days.
  • CDTX ranks lowest in Momentum; there it ranks in the 4th percentile.

CDTX Stock Summary

  • Of note is the ratio of Cidara Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 7.94% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for Cidara Therapeutics Inc comes in at 310.81%, a number that bests 97.4% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CDTX comes in at -76.53% -- higher than that of only 5.41% of stocks in our set.
  • Stocks that are quantitatively similar to CDTX, based on their financial statements, market capitalization, and price volatility, are XCUR, CBIO, IVA, ZYME, and AFMD.
  • Visit CDTX's SEC page to see the company's official filings. To visit the company's web site, go to www.cidara.com.

CDTX Valuation Summary

  • In comparison to the median Healthcare stock, CDTX's EV/EBIT ratio is 104.78% lower, now standing at -1.4.
  • CDTX's price/earnings ratio has moved up 14.8 over the prior 78 months.
  • CDTX's price/earnings ratio has moved up 14.8 over the prior 78 months.

Below are key valuation metrics over time for CDTX.

Stock Date P/S P/B P/E EV/EBIT
CDTX 2021-08-31 2.8 7.2 -2.3 -1.4
CDTX 2021-08-30 2.6 6.8 -2.2 -1.3
CDTX 2021-08-27 2.5 6.6 -2.1 -1.2
CDTX 2021-08-26 2.5 6.4 -2.1 -1.2
CDTX 2021-08-25 2.6 6.8 -2.2 -1.3
CDTX 2021-08-24 2.5 6.5 -2.1 -1.2

CDTX Growth Metrics

    Its 2 year price growth rate is now at -22.89%.
  • The 5 year cash and equivalents growth rate now stands at 43.73%.
  • Its 3 year price growth rate is now at -81.46%.
CDTX's revenue has moved up $49,572,000 over the prior 70 months.

The table below shows CDTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 49.572 -25.232 -42.467
2021-09-30 46.076 -21.453 -49.19
2021-06-30 41.416 -23.564 -48.739
2021-03-31 11.945 -41.076 -75.864
2020-12-31 12.067 -54.411 -74.873
2020-09-30 10.153 -58.48 -67.262

CDTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDTX has a Quality Grade of B, ranking ahead of 87.28% of graded US stocks.
  • CDTX's asset turnover comes in at 0.684 -- ranking 42nd of 682 Pharmaceutical Products stocks.
  • VNRX, PBH, and NVS are the stocks whose asset turnover ratios are most correlated with CDTX.

The table below shows CDTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.684 1 2.529
2021-03-31 0.190 1 4.489
2020-12-31 0.171 1 6.027
2020-09-30 0.140 1 5.823
2020-06-30 0.348 1 4.233
2020-03-31 0.327 1 5.374

CDTX Price Target

For more insight on analysts targets of CDTX, see our CDTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.36 (Strong Buy)

CDTX Stock Price Chart Interactive Chart >

Price chart for CDTX

CDTX Price/Volume Stats

Current price $0.45 52-week high $2.39
Prev. close $0.46 52-week low $0.41
Day low $0.44 Volume 137,600
Day high $0.46 Avg. volume 302,635
50-day MA $0.73 Dividend yield N/A
200-day MA $1.26 Market Cap 30.99M

Cidara Therapeutics, Inc. (CDTX) Company Bio


Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. The company was founded in 2012 and is based in San Diego, California.


CDTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CDTX Latest Social Stream


Loading social stream, please wait...

View Full CDTX Social Stream

Latest CDTX News From Around the Web

Below are the latest news stories about Cidara Therapeutics Inc that investors may wish to consider to help them evaluate CDTX as an investment opportunity.

Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

H.C. Wainwright Thinks Cidara Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) yesterday and set a price target of $7.50. The company's shares closed last Monday at $0.80, close to its 52-week low of $0.76. According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.0% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $6.75, a 738.5% upside from current levels.

Howard Kim on TipRanks | February 15, 2022

FDA Clears Cidara Therapeutics'' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza

The FDA has signed off Cidara Therapeutics Inc'' s (NASDAQ: CDTX ) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company. Cidara Full story available on Benzinga.com

Benzinga | February 14, 2022

Cidara announces FDA acceptance of its request to study the flu candidate

Cidara Therapeutics (CDTX) is trading ~3% higher in the pre-market on Monday after the company announced that the FDA accepted its Investigational New Drug ((IND)) application for the…

Seeking Alpha | February 14, 2022

FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza

The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company. Cidara intends to initiate a Phase 1 study in healthy volunteers before the end of the current quarter. Related: Cidara Therapeutics Stock Slides Despite Acin

Yahoo | February 14, 2022

Read More 'CDTX' Stories Here

CDTX Price Returns

1-mo -41.91%
3-mo -36.07%
6-mo -69.39%
1-year -77.61%
3-year -76.56%
5-year -93.33%
YTD -64.57%
2021 -36.50%
2020 -47.92%
2019 63.40%
2018 -65.44%
2017 -34.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4795 seconds.